Human medicines European public assessment report (EPAR): Neofordex, dexamethasone, Date of authorisation: 16/03/2016, Revision: 12, Status: Authorised
Human medicines European public assessment report (EPAR): Copiktra, duvelisib, Date of authorisation: 19/05/2021, Revision: 3, Status: Withdrawn
Human medicines European public assessment report (EPAR): Ondibta, insulin glargine, Date of authorisation: 09/01/2026, Status: Authorised
Core summary of product characteristics for human normal immunoglobulin for subcutaneous and intramuscular use - Scientific guideline
Clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg) - Scientific guideline
Template for sharing EMA documents by Industry to support reliance
Clinical Trial Information System (CTIS) - Sponsor Frequently Asked Questions (FAQ)
We are pleased to share that ECIM 2026 has been featured in six articles published on Medscape. These articles showcase the different scientific discussions and research presented during the congress.
The Medscape coverage reflects the relevance and impact of the presentations delivered at the ECIM 2026, helping expand their visbility to a wider audience.
Please find the Medscape articles in the link below:
Human medicines European public assessment report (EPAR): Theralugand, lutetium (177Lu) chloride, Date of authorisation: 22/11/2024, Revision: 1, Status: Authorised
PRIME: priority medicines